Jan 11, 2021
TORONTO, ON / ACCESSWIRE / January 11, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received approval from the Ministry of Health (INVIMA) in Colombia to expand the clinical trial of its investigational drug EB05 in hospitalized COVID-19 patients. The stu...
Dec 30, 2020
TORONTO, ON / ACCESSWIRE / December 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, Par Nijhawan, providing a review of 2020.
Dec 7, 2020
TORONTO, ON / ACCESSWIRE / December 7, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the fiscal year ended September 30, 2020 and provided an update on its business.
Nov 30, 2020
TORONTO, ON / ACCESSWIRE / November 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2/Phase3 clinical trial evaluating the company's investigational drug, EB05, as a therapy for hospitalized...
Nov 6, 2020
TORONTO, ON / ACCESSWIRE / November 6, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to present at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020 at 12:30 pm ET...
Nov 3, 2020
TORONTO, ON / ACCESSWIRE / November 3, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment of more than 50% of the patients planned for the first cohort of a Phase 2b clinical study evaluating the company's drug candi...
Oct 19, 2020
TORONTO, ON / ACCESSWIRE / October 19, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received clearance from the U.S. Food and Drug Administration (FDA) to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05, for the...
Aug 12, 2020
TORONTO, ON / ACCESSWIRE / August 12, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and nine months ended June 30, 2020 and provided an update on its business.